Walter M. Stadler, MD, FACP | Authors

BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA-OU PHYSICIANS

OUPB 2500

825 NE 10TH ST

Articles

Renal Cancer Therapeutics: Now What?

March 13, 2012

The development of vascular endothelial growth factor (VEGF) pathway inhibitors and mammalian target of rapamycin (mTOR) inhibitors for the treatment of renal cancer is a real success story.